{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T15:24:59Z","timestamp":1791645899979,"version":"4.3.4"},"reference-count":52,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,5]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>Current treatment modalities in Beh\u00e7et's disease will be summarized in light of new studies published within the last 2 years.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>There is an increasing interest in the treatment of refractory mucocutaneous symptoms of Beh\u00e7et's disease, and results were quite promising with apremilast, anakinra, and ustekinumab. Data from large case series confirmed both the efficacy and safety of tumor necrosis factor-\u03b1 inhibitors for the treatment of refractory major organ manifestations such as ocular, neurologic, vascular, and gastrointestinal involvement. In refractory ocular disease, long-term results also confirmed the efficacy and safety of interferon-\u03b1. Interleukin-1 inhibitors and tocilizumab seem to be alternative options in patients with refractory ocular involvement.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>Prospective and controlled studies for the management of major organ involvement in Beh\u00e7et's disease are still limited. Data from primarily retrospective studies confirmed better outcomes of major organ involvement with tumor necrosis factor-\u03b1 inhibitors and interferon-\u03b1. There were also acceptable results with interleukin-1 inhibitors for the management of refractory ocular disease, and with apremilast, anakinra, and ustekinumab for refractory mucocutaneous involvement.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/bor.0000000000000497","type":"journal-article","created":{"date-parts":[[2018,2,11]],"date-time":"2018-02-11T13:16:46Z","timestamp":1518355006000},"page":"238-242","source":"Crossref","is-referenced-by-count":27,"title":["Management of Beh\u00e7et's disease"],"prefix":"10.1097","volume":"30","author":[{"given":"Fatma","family":"Alibaz-Oner","sequence":"first","affiliation":[{"name":"Division of Rheumatology, School of Medicine, Marmara University, Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amr H.","family":"Sawalha","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haner","family":"Direskeneli","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, School of Medicine, Marmara University, Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230828","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1097\/00005792-200301000-00006","article-title":"The long-term mortality and morbidity of Behcet syndrome: a 2-decade outcome survey of 387 patients followed at a dedicated center","volume":"82","author":"Kural-Seyahi","year":"2003","journal-title":"Medicine (Baltimore)"},{"key":"R2-20230828","doi-asserted-by":"crossref","first-page":"2686","DOI":"10.1002\/1529-0131(200111)44:11<2686::AID-ART448>3.0.CO;2-H","article-title":"A double-blind trial of colchicine in Beh\u00e7et's syndrome","volume":"44","author":"Yurdakul","year":"2001","journal-title":"Arthritis Rheum"},{"key":"R3-20230828","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1136\/ard.2007.080432","article-title":"EULAR recommendations for the management of Beh\u00e7et disease","volume":"67","author":"Hatemi","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"R4-20230828","doi-asserted-by":"crossref","first-page":"443","DOI":"10.7326\/0003-4819-128-6-199803150-00004","article-title":"Thalidomide in the treatment of the mucocutaneous lesions of the Beh\u00e7et syndrome. A randomized, double-blind, placebo-controlled trial","volume":"128","author":"Hamuryudan","year":"1998","journal-title":"Ann Intern Med"},{"key":"R5-20230828","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1056\/NEJMoa1408684","article-title":"Apremilast for Beh\u00e7et's syndrome \u2013 a phase 2, placebo-controlled study","volume":"372","author":"Hatemi","year":"2015","journal-title":"N Engl J Med"},{"key":"R6-20230828","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s13075-017-1222-3","article-title":"Treatment of mucocutaneous manifestations in Beh\u00e7et's disease with anakinra: a pilot open-label study","volume":"19","author":"Grayson","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"R7-20230828","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.jaut.2017.05.002","article-title":"Ustekinumab for Beh\u00e7et's disease","volume":"82","author":"Mirouse","year":"2017","journal-title":"J Autoimmun"},{"key":"R8-20230828","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1080\/13543784.2016.1181751","article-title":"New therapeutic solutions for Beh\u00e7et's syndrome","volume":"25","author":"Vitale","year":"2016","journal-title":"Expert Opin Investig Drugs"},{"key":"R9-20230828","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1002\/art.39667","article-title":"Infliximab versus adalimumab in the treatment of refractory inflammatory uveitis: a multicenter study from the French Uveitis Network","volume":"68","author":"Vallet","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"R10-20230828","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s10067-016-3417-4","article-title":"Adalimumab effectiveness in Beh\u00e7et's disease: short and long-term data from a multicenter retrospective observational study","volume":"36","author":"Vitale","year":"2017","journal-title":"Clin Rheumatol"},{"key":"R11-20230828","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s10067-016-3480-x","article-title":"Efficacy and safety of adalimumab in Beh\u00e7et's disease-related uveitis: a multicenter retrospective observational study","volume":"36","author":"Fabiani","year":"2017","journal-title":"Clin Rheumatol"},{"key":"R12-20230828","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1056\/NEJMoa1509852","article-title":"Adalimumab in patients with active noninfectious uveitis. Adalimumab for prevention of uveitic flare in patients with inactive noninfectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial","volume":"375","author":"Jaffe","year":"2016","journal-title":"N Engl J Med"},{"key":"R13-20230828","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/S0140-6736(16)31339-3","article-title":"Adalimumab for prevention of uveitic flare in patients with inactive noninfectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial","volume":"388","author":"Nguyen","year":"2016","journal-title":"Lancet"},{"key":"R14-20230828","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1080\/09273948.2016.1239746","article-title":"Efficacy of infliximab for early remission induction in refractory uveoretinitis associated with Beh\u00e7et disease: a 2-year follow-up study","volume":"25","author":"Keino","year":"2017","journal-title":"Ocul Immunol Inflamm"},{"issue":"(Suppl 108)","key":"R15-20230828","first-page":"86","article-title":"Infliximab for uveitis of Beh\u00e7et's syndrome: a trend for earlier initiation","volume":"35","author":"Guzelant","year":"2017","journal-title":"Clin Exp Rheumatol"},{"key":"R16-20230828","first-page":"1","article-title":"Intravitreal adalimumab for the control of breakthrough intraocular inflammation","author":"Kheir","year":"2017","journal-title":"Ocul Immunol Inflamm"},{"key":"R17-20230828","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3109\/09273948.2015.1133835","article-title":"Interferon alpha-2a therapy in patients with refractory Beh\u00e7et uveitis","volume":"25","author":"Hasanreisoglu","year":"2017","journal-title":"Ocul Immunol Inflamm"},{"key":"R18-20230828","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1080\/09273948.2016.1206204","article-title":"Long-term efficacy of interferon in severe uveitis associated with Beh\u00e7et disease","volume":"25","author":"Diwo","year":"2017","journal-title":"Ocul Immunol Inflamm"},{"key":"R19-20230828","first-page":"1","article-title":"Long-term efficacy of pegylated interferon alpha-2b in Beh\u00e7et's uveitis: a small case series","author":"Celiker","year":"2017","journal-title":"Ocul Immunol Inflamm"},{"key":"R20-20230828","first-page":"599","article-title":"Potential of pegylated interferon alpha-2a in Beh\u00e7et uveitis: a report of five cases","volume":"24","author":"Bielefeld","year":"2016","journal-title":"Ocul Immunol Inflamm"},{"key":"R21-20230828","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s10067-016-3506-4","article-title":"Interleukin (IL)-1 inhibition with anakinra and canakinumab in Beh\u00e7et's disease-related uveitis: a multicenter retrospective observational study","volume":"36","author":"Fabiani","year":"2017","journal-title":"Clin Rheumatol"},{"key":"R22-20230828","doi-asserted-by":"crossref","first-page":"62","DOI":"10.3109\/09273948.2015.1092558","article-title":"Safety and efficacy of gevokizumab in patients with Beh\u00e7et's disease uveitis: results of an exploratory phase 2 study","volume":"25","author":"Tugal-Tutkun","year":"2017","journal-title":"Ocul Immunol Inflamm"},{"key":"R23-20230828","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1111\/1756-185X.13095","article-title":"High-dose intravenous steroid pulse therapy in ocular involvement of Behcet's disease: a pilot double-blind controlled study","volume":"20","author":"Mohammadi","year":"2017","journal-title":"Int J Rheum Dis"},{"key":"R24-20230828","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.3899\/jrheum.141344","article-title":"Alemtuzumab as remission induction therapy in Beh\u00e7et disease: a 20-year experience","volume":"42","author":"Mohammad","year":"2015","journal-title":"J Rheumatol"},{"key":"R25-20230828","first-page":"1","article-title":"Tocilizumab for the treatment of Beh\u00e7et uveitis that failed interferon alpha and anti-tumor necrosis factor-alpha therapy","author":"Eser Ozturk","year":"2017","journal-title":"Ocul Immunol Inflamm"},{"key":"R26-20230828","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.semarthrit.2015.11.012","article-title":"Tocilizumab in severe and refractory Behcet's disease: four cases and literature review","volume":"45","author":"Deroux","year":"2016","journal-title":"Semin Arthritis Rheum"},{"issue":"(6 Suppl 102)","key":"R27-20230828","first-page":"S34","article-title":"The effect of biologic therapy different from infliximab or adalimumab in patients with refractory uveitis due to Beh\u00e7et's disease: results of a multicentre open-label study","volume":"34","author":"Santos-G\u00f3mez","year":"2016","journal-title":"Clin Exp Rheumatol"},{"key":"R28-20230828","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1097\/BOR.0000000000000050","article-title":"Management of Beh\u00e7et's syndrome","volume":"26","author":"Ozguler","year":"2014","journal-title":"Curr Opin Rheumatol"},{"key":"R29-20230828","doi-asserted-by":"crossref","first-page":"e494","DOI":"10.1097\/MD.0000000000000494","article-title":"Beh\u00e7et disease with vascular involvement: effects of different therapeutic regimens on the incidence of new relapses","volume":"94","author":"Alibaz-Oner","year":"2015","journal-title":"Medicine (Baltimore)"},{"key":"R30-20230828","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.semarthrit.2015.06.008","article-title":"Pulmonary artery involvement in Behcet's syndrome: effects of anti-TNF treatment","volume":"45","author":"Hamuryudan","year":"2015","journal-title":"Semin Arthritis Rheum"},{"key":"R31-20230828","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1002\/acr.21557","article-title":"Behcet's disease: successful treatment with infliximab in 7 patients with severe vascular manifestations. A retrospective analysis","volume":"64","author":"Adler","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"R32-20230828","doi-asserted-by":"crossref","first-page":"e3863","DOI":"10.1097\/MD.0000000000003863","article-title":"Infliximab therapy for intestinal, neurological, and vascular involvement in Behcet disease: Efficacy, safety, and pharmacokinetics in a multicenter, prospective, open-label, single-arm phase 3 study","volume":"95","author":"Hibi","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"R33-20230828","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1080\/14712598.2017.1328496","article-title":"Management of severe complications in Beh\u00e7et's disease with TNF inhibitors","volume":"17","author":"Desbois","year":"2017","journal-title":"Expert Opin Biol Ther"},{"key":"R34-20230828","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.autrev.2016.01.003","article-title":"Pulmonary artery aneurysms in Beh\u00e7et's disease treated with anti-TNF\u03b1: a case series and review of the literature","volume":"15","author":"Chan","year":"2016","journal-title":"Autoimmun Rev"},{"key":"R35-20230828","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1007\/s10067-013-2443-8","article-title":"Anakinra treatment in drug-resistant Behcet's disease: a case series","volume":"34","author":"Cantarini","year":"2015","journal-title":"Clin Rheumatol"},{"key":"R36-20230828","article-title":"Outcomes of patients with Beh\u00e7et's syndrome after pulmonary endarterectomy","author":"Yildizeli","year":"2017","journal-title":"Thorac Cardiovasc Surg"},{"key":"R37-20230828","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1007\/s11940-011-0120-2","article-title":"Beh\u00e7et's disease","volume":"13","author":"Akman-Demir","year":"2011","journal-title":"Curr Treat Options Neurol"},{"key":"R38-20230828","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1007\/s00415-013-7209-3","article-title":"Diagnosis and management of neuro-Beh\u00e7et's disease: international consensus recommendations","volume":"261","author":"Kalra","year":"2014","journal-title":"J Neurol"},{"key":"R39-20230828","doi-asserted-by":"crossref","first-page":"e258","DOI":"10.1212\/NXI.0000000000000258","article-title":"Infliximab is a plausible alternative for neurologic complications of Beh\u00e7et disease","volume":"3","author":"Zeydan","year":"2016","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"R40-20230828","doi-asserted-by":"crossref","first-page":"e3550","DOI":"10.1097\/MD.0000000000003550","article-title":"Efficacy of anti-TNF\u03b1 in severe and refractory neuro-behcet disease: an observational study","volume":"95","author":"Desbois","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"R41-20230828","first-page":"367","article-title":"Severe neuro-Behcet's disease treated with a combination of immunosuppressives and a TNF-inhibitor","volume":"41","author":"Korkmaz","year":"2016","journal-title":"Acta Reumatol Port"},{"key":"R42-20230828","doi-asserted-by":"crossref","first-page":"524","DOI":"10.3899\/jrheum.150177","article-title":"Characteristics predicting tuberculosis risk under tumor necrosis factor-\u03b1 inhibitors: report from a large multicenter cohort with high background prevalence","volume":"43","author":"Kisacik","year":"2016","journal-title":"J Rheumatol"},{"key":"R43-20230828","first-page":"238","article-title":"Efficacy and safety of intravenous immunoglobulin treatment in refractory Behcet's disease with different organ involvement: a case series","volume":"18","author":"Cantarini","year":"2016","journal-title":"Isr Med Assoc J"},{"key":"R44-20230828","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jocn.2016.03.020","article-title":"Neuro-Beh\u00e7et's disease presenting with tumour-like lesions and responding to rituximab","volume":"32","author":"Jade","year":"2016","journal-title":"J Clin Neurosci"},{"key":"R45-20230828","doi-asserted-by":"crossref","first-page":"2676","DOI":"10.1007\/s00415-015-7897-y","article-title":"Rituximab is effective in severe treatment-resistant neurological Beh\u00e7et's syndrome","volume":"262","author":"Kidd","year":"2015","journal-title":"J Neurol"},{"key":"R46-20230828","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1097\/MCG.0b013e3182431d56","article-title":"Long-term clinical outcomes and factors predictive of relapse after 5-aminosalicylate or sulfasalazine therapy in patients with intestinal Behcet disease","volume":"46","author":"Jung","year":"2012","journal-title":"J Clin Gastroenterol"},{"key":"R47-20230828","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1002\/ibd.21757","article-title":"Clinical outcomes and prognostic factors for thiopurine maintenance therapy in patients with intestinal Behcet's disease","volume":"18","author":"Jung","year":"2012","journal-title":"Inflamm Bowel Dis"},{"issue":"(6 Suppl 94)","key":"R48-20230828","first-page":"S129","article-title":"TNF-alpha antagonists and thalidomide for the management of gastrointestinal Beh\u00e7et's syndrome refractory to the conventional treatment modalities: a case series and review of the literature","volume":"33","author":"Hatemi","year":"2015","journal-title":"Clin Exp Rheumatol"},{"key":"R49-20230828","doi-asserted-by":"crossref","first-page":"e3348","DOI":"10.1097\/MD.0000000000003348","article-title":"Characteristics, treatment, and long-term outcome of gastrointestinal involvement in behcet's syndrome: a strobe-compliant observational study from a dedicated Multidisciplinary Center","volume":"95","author":"Hatemi","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"R50-20230828","doi-asserted-by":"crossref","first-page":"395","DOI":"10.5217\/ir.2017.15.3.395","article-title":"Long-term safety and efficacy of adalimumab for intestinal Beh\u00e7et's disease in the open label study following a phase 3 clinical trial","volume":"15","author":"Inoue","year":"2017","journal-title":"Intest Res"},{"key":"R51-20230828","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s10620-016-4395-8","article-title":"Long-term outcomes and predictors of sustained response in patients with intestinal Behcet's disease treated with infliximab","volume":"62","author":"Zou","year":"2017","journal-title":"Dig Dis Sci"},{"key":"R52-20230828","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1002\/art.40235","article-title":"Brief Report: Drug-free long-term remission in severe Behcet's disease following withdrawal of successful anti\u2013tumor necrosis factor treatment","volume":"69","author":"Sfikakis","year":"2017","journal-title":"Arthritis Rheum"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00002281-201805000-00004","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,28]],"date-time":"2023-08-28T05:06:16Z","timestamp":1693199176000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00002281-201805000-00004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":52,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/bor.0000000000000497","relation":{},"ISSN":["1040-8711","1531-6963"],"issn-type":[{"value":"1040-8711","type":"print"},{"value":"1531-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5]]}}}